OA06.07 Stereotactic Ablative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts

B Kidane,J Spicer,J.O Kim,I.J Gerard,B Abdulkarim,P.-O Fiset,M.J Cecchini,R.A Malthaner,R.I Inculet,E Wakeam,D Fortin,P Wawryko,G Qing,D.A Palma

doi:10.1016/j.jtho.2022.07.039

OA06.07 Stereotactic Ablative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts

B Kidane, J Spicer + Show 12 more

Open Access

https://doi.org/10.1016/j.jtho.2022.07.039

Copy DOI

Journal: Journal of Thoracic Oncology	Publication Date: Sep 1, 2022
License type: NO-CC CODE

Affiliation: CancerCare Manitoba, McGill University, Western University of Health Sciences, University of Michigan–Ann Arbor, University of Manitoba

#Stereotactic Ablative Radiotherapy #Prospective Data Collection + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The COVID-19 pandemic led to worldwide barriers to access to operating rooms; some multidisciplinary thoracic oncology teams pivoted to a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to provide radical-intent treatment combining immediate SABR followed by planned surgery when surgical resource constraints ameliorated. This pragmatic approach, termed SABR-BRIDGE, was instituted with prospective data collection at four institutions (3 Canada, 1 USA); herein we present the surgical and pathological results from this approach.

Full Text